Nassar AH, Bou Farhat E, Abushukair H, Alchoueriy M, Salem S, Machaalani M, Adib E, Henske EP, Babu P, Choueiri TK, Rakaee M, Busund LR, Takabe Y, Lau SF, Rall K, Naqash AR, Jansen C, Wang X, Challa P, Tarantino P, Partridge AH, Tolaney SM, Kwiatkowski DJ, Winer EP (2025)
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer
J Natl Cancer Inst (in press)
DOI 10.1093/jnci/djaf344, PubMed 41418409

Romero-Becerra R, Zhao Z, Nebdal D, Müller E, Bergholtz H, Norum JH, Aittokallio T (2025)
Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool
Nat Commun, 16 (1), 10151
DOI 10.1038/s41467-025-65218-9, PubMed 41258298

Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Aanerud M, Ahvonen J, Silvoniemi M, Bjaanæs MM, Farooqi S, Nebdal D, Dalsgaard AM, Danielsen BK, Børve M, Dalen TS, Öjlert ÅK, Helland Å (2025)
Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab
Front Oncol, 15, 1681420
DOI 10.3389/fonc.2025.1681420, PubMed 41199847